Technology, Healthcare Aug 27, 2021 10:39 PM (GMT+8) · EqualOcean
Financial Associated Press, August 27 - Huadong pharmaceutical received a regulatory inquiry letter. Zhejiang Securities Regulatory Bureau asked the company to explain in detail the specific circumstances of the disputes related to the dissolution between the company and East China Ningbo, including but not limited to the reasons for the repeated extension of the business term, the phased intention reached by both parties and the reasons for stopping the equity acquisition; Explain whether the company has lost control over East China Ningbo and whether the company has taken corresponding measures to ensure the stable operation of East China Ningbo.
Related companies: